Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia

June 2019 in “ JAMA Dermatology ”

Azael Freites-Martínez, Donald Chan, V. Sibaud, Jerry Shapiro, Gabriella Fabbrocini, Antonella Tosti, Juhee Cho, Shari Goldfarb, Shanu Modi, Devika Gajria, Larry Norton, Ralf Paus, Tessa Cigler, Mario E. Lacouture

persistent chemotherapy-induced alopecia endocrine therapy-induced alopecia taxanes aromatase inhibitors topical minoxidil spironolactone pCIA EIAC Rogaine

TLDR Hair regrowth treatments had modest benefits for patients with long-term hair loss after chemotherapy.

The study "Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia" from June 2019 involved 192 female cancer patients who developed persistent alopecia after chemotherapy. The study found that persistent chemotherapy-induced alopecia (pCIA) was more severe and diffuse than endocrine therapy-induced alopecia after chemotherapy (EIAC), with 82% of pCIA cases associated with taxanes and 62% of EIAC cases associated with aromatase inhibitors. Both groups reported a negative emotional impact. After treatment with topical minoxidil or spironolactone, 67% of pCIA patients and 76% of EIAC patients observed moderate to significant hair regrowth. However, the study concluded that while these treatments showed modest benefits, further research is needed to develop more effective prevention and treatment strategies for pCIA and EIAC.

View this study on jamanetwork.com →

Discuss this study in the Community →

Cited in this study

9 / 9 results

research Safety of 5α-Reductase Inhibitors and Spironolactone in Breast Cancer Patients Receiving Endocrine Therapies

22 citations , November 2018 in “Breast Cancer Research and Treatment”

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

research Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer

67 citations , June 2018 in “JAMA Dermatology”

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

research Madarosis: A Qualitative Study to Assess Perceptions and Experience of Australian Patients with Early Breast Cancer Treated with Taxane-Based Chemotherapy

11 citations , August 2017 in “Supportive care in cancer”

Madarosis (eyebrow and eyelash loss) significantly affects quality of life for breast cancer patients on taxane-based chemotherapy.

research Permanent Alopecia in Patients with Breast Cancer After Taxane Chemotherapy and Adjuvant Hormonal Therapy: Clinicopathologic Findings in a Cohort of 10 Patients

31 citations , May 2017 in “Journal of The American Academy of Dermatology”

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

research Docetaxel and Permanent Alopecia

8 citations , May 2013 in “Journal of The American Academy of Dermatology”

Some breast cancer patients treated with high-dose docetaxel may experience permanent hair loss.

research Pathobiology of Chemotherapy-Induced Hair Loss

218 citations , February 2013 in “The Lancet Oncology”

Chemotherapy causes hair loss by damaging hair follicles and stem cells, with more research needed for prevention and treatment.

research A Randomized Evaluator Blinded Study of Effect of Microneedling in Androgenetic Alopecia: A Pilot Study

136 citations , January 2013 in “International Journal of Trichology”

research Assessment of Hair Density and Caliber in Caucasian and Asian Female Subjects with Female Pattern Hair Loss Using the Folliscope

24 citations , January 2012 in “Journal of The American Academy of Dermatology”

Caucasian hair is denser, but Asian hair is thicker in female pattern hair loss patients.

research A New Classification of Pattern Hair Loss That Is Universal for Men and Women: Basic and Specific (BASP) Classification

125 citations , July 2007 in “Journal of The American Academy of Dermatology”

The BASP classification is a detailed and accurate way to categorize hair loss in both men and women.

7 / 7 results

research Diffuse Hair Loss

January 2022 in “Elsevier eBooks”

The document's conclusion cannot be summarized because it is not readable or understandable.

research Hair Loss

August 2021 in “Pharmacy Today”

The document's conclusion about hair loss cannot be determined.

research Treatment of Female Pattern Hair Loss with Combination Therapy

2 citations , December 2018 in “Seminars in Cutaneous Medicine and Surgery”

research A Review on Hair Loss and Damage

January 2016

The article concludes that understanding the causes of hair loss and using continuous treatments like minoxidil and finasteride can help manage it, despite potential side effects.

research Common Patterns and Etiologic Factors of Hair Loss for Women in Karak Governorate, Jordan

January 2015 in “Rawal Medical Journal”

research Viviscal: An Answer for Hair Loss in Women?

August 2013 in “Pharmacy Today”

Viviscal may modestly improve hair loss in women without adverse effects.

research Drugs and Hair Loss: Mechanisms and Clinical Implications

54 citations , January 2013 in “Dermatologic Clinics”

Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.